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Abstract A lowered efficiency of oxidative phosphorylation was 
recently found in a Leber hereditary optic neuropathy (LHON) 
proband carrying a mutation in the mtDNA gene for subunit 6 of 
the membrane-bound Fo segment of the FiFo-ATP synthase [9]. 
This phenotype was transferred to cytoplasmic hybrid cells 
together with the mutation, proving its functional significance. 
Increasing the respiratory rate in the mitochondria from this 
mutant raised the ATP/2e ratio back to normal values. A 
different mutation in the same mtDNA gene has been found in 
patients with the NARP syndrome [10]. Although the ATP/2e 
ratio is also decreased in this mutant, in this case an increase in 
the respiratory rate could not compensate for it. Whilst both 
mutations affect subunit 6 of the proton-translocating Fo 
segment, the LHON mutation induces a proton leak whereas 
the NARP mutation blocks proton translocation. Hence, the 
latter will have much more destructive metabolic consequences in 
agreement with the large clinical differences between the two 
diseases. 
© 1997 Federation of European Biochemical Societies. 
Key words: F 0 ; Leber's disease; Leber hereditary optic 
neuropathy; Mitochondrial disease; NARP syndrome; 
Proton translocation 
1. Introduction 
Mitochondrial oxidative phosphorylation fulfils most of the 
energy requirement of eukaryotic cells. Cell respiration gener-
ates an electrochemical proton gradient across the inner mi-
tochondrial membrane, and the FiFo-ATP synthase utilizes 
this proton gradient by catalysing ATP synthesis from ADP 
plus inorganic phosphate coupled to influx of protons. Thir-
teen polypeptides of the respiratory chain complexes, and of 
the FjF0-ATP synthase, are encoded by human mitochondrial 
DNA (mtDNA; [1]). 
The Leber hereditary optic neuropathy (LHON) is a mito-
chondrial disease that results in bilateral optic nerve atrophy 
in young, usually male, adults. The condition appears quite 
specific, although cardiac and neurological symptoms are ob-
served in some patients [2]. Several homoplasmic mutations in 
the structural genes of mtDNA have been associated with 
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LHON, suggesting a bioenergetic basis for its pathogenesis. 
Until recently, all these mutations have been found in the 
respiratory chain complexes. In these cases the rate of respi-
ration and, consequently, that of oxidative ATP synthesis is 
reduced, but only with limited severity [3-8]. Notably, the 
efficiency of oxidative phosphorylation (ATP/2e~ ratio) is un-
altered. 
Recently, a point mutation at nucleotide (nt) 9101 of the 
mtDNA gene that encodes subunit 6 of the F^o-ATP syn-
thase was found in one LHON family [9]. This was associated 
with a lowered efficiency of oxidative phosphorylation in lym-
phoblast mitochondria, which is consistent with a defect in the 
FiFo-ATP synthase. Except for general polymorphisms, no 
other protein-encoding mutations were found in the mtDNA 
of the LHON patients [9]. 
Interestingly, mutation of another site in subunit 6 of the 
ATP synthase has also been linked to mitochondrial disease. 
Thus, the nt 8993 mutations T->C and T->G have been 
associated with Leigh's disease, and with a syndrome termed 
NARP (neurogenic weakness, ataxia and retinitis pigmentosa; 
[10-13]). The clinical manifestations of the T->G mutation 
have been studied in four generations of a Finnish family, 
in which a wide range of presentations from suboptimal 
dark adaptation to severe encephalopathy was observed, de-
pending on the degree of heteroplasmy [12]. In complete con-
trast to this, the patient with the nt 9101 mutation represents 
a typical case of LOHN. 
Here we show by the cytoplasmic hybrid (cybrid) cell ap-
proach [14,15] that the defect in the LHON case is truly car-
ried by the mitochondrial DNA. Comparison of the function-
al defects due to the two mutations in subunit 6 of the ATP 
synthase reveal that they are completely different in nature, 
which may help to explain why they lead to very different 
diseases. 
2. Materials and methods 
Mitochondria were isolated and uncoupler-sensitive ATP synthesis 
and electron transfer determined as in [5]. 
An rho° cell line devoid of mtDNA (143BTK; provided by I. 
Trounce) was produced as in [14]. Cybrid cells were made from 
enucleated LHON patient or control lymphoblasts (cytoplasts) and 
rho° cells, essentially as described by Trounce et al. [15]. Screening 
for the nt 9101 mutation in cybrid cells was done after amplification 
with primers nt 8973-8991 and nt 9292-9276. After digestion with 
Hph\, the mtDNA fragments were separated on agarose gels and 
visualised under UV light. Samples with the nt 9101 mutation yielded 
fragments of 128 and 192 basepairs (bp). Samples without the muta-
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tion remained uncut, producing a single 320 bp fragment. All single 
cybrid colonies derived from LHON cytoplasts were homoplasmic for 
the nt 9101 mutation. All control cybrids lacked this mutation. 
3. Results and discussion 
To determine whether the functional defect in the LHON 
case is truly due to a mtDNA mutation, and not to mutations 
in nuclear genes of the FiFo-ATP synthase, we used the cy-
brid approach [14,15]. Enucleated cells from the patient or 
from a control were fused with rho° cells that lack mtDNA, 
and oxidative phosphorylation was studied in mitochondria 
isolated from the resulting cybrid cells. As shown in Table 
1, these mitochondria indeed exhibited a lowered efficiency 
of oxidative phosphorylation, which demonstrates conclu-
sively that the defect is carried with the mutant mitochondria. 
A functional defect in the ATP synthase should be inde-
pendent of the segment of the respiratory chain that generates 
the electrochemical proton gradient. This is confirmed by the 
finding that the efficiency of ATP synthesis in the mutant is 
significantly lowered also when coupled to the oxidation of 
ferrocytochrome c by O2 (Table 1). 
Since the clinical manifestations of the two ATP synthase 
subunit 6 mutations are very different, it was of interest to 
compare their functional consequences. We found that the 
rates of respiration in the controlled state (state 4), during 
oxidative phosphorylation (state 3), and in the presence of 
an uncoupling agent, were essentially normal in nt 9101 and 
nt 8993 mutant lymphoblast mitochondria (not shown). The 
only exception was that state 3 respiration was slightly slower 
in nt 8993 mutant mitochondria. Apparently the lowered ATP 
synthase activity in this mutant causes some secondary inhi-
bition of coupled respiration, in agreement with the finding of 
Trounce et al. [13]. Although much weaker, this effect is thus 
analogous to that of the well-known Fo inhibitor oligomycin. 
An increase of the rate of mitochondrial respiration is nor-
mally accompanied by a proportional rise in the rate of ATP 
synthesis (Fig. 1A). In the control, the ATP/2e~ ratio is close 
to unity (Fig. 2), which is the known value when ATP syn-
thesis is linked to the cytochrome C-O2 span of the respiratory 
chain [16]. Comparison of the rate of ATP synthesis with the 
rate of respiration revealed a striking difference between the 
two subunit 6 mutations. In the nt 9101 mutant mitochondria 
the ATP/2e~ ratio is significantly lower than in the controls at 
low respiratory rates, but rises towards unity at high respira-
tory rates (Figs. IB and 2). In this case, therefore, an elevated 
rate of respiration is able to compensate for the lowered effi-
ciency of ATP synthesis. 
The nt 8993 mutant mitochondria behave very differently. 
The ATP/2e~ ratio is almost normal at the lowest respiratory 
rates, but increasing the respiratory velocity now causes only a 
very small increase in the rate of ATP synthesis (Fig. 1C). 
Hence, the ATP/2e~ ratio drops to a low value (cf. [13]), 
similar to that in the nt 9101 mutant at low respiratory rate 
(Fig. 2). 
Subunit 6 is an essential part of the membrane-bound F0 
domain of the ATP synthase complex, and corresponds to 
subunit a in the homologous bacterial and chloroplast en-
zymes. It is a highly hydrophobic polypeptide of unknown 
structure, and interacts closely with the oligomeric subunit 
c. Both these subunits have been shown to be intimately in-
volved in proton translocation catalysed by the F0 domain 
[17], which drives the synthesis of ATP in the Fi domain, 
possibly by a rotational mechanism [18,19]. 
Positions 156 (affected by the nt 8993 mutation) and 192 
(affected by the nt 9101 mutation) are both among the last 80 
amino acids in the carboxy-terminus of subunit 6. Mutagen-
esis work in bacteria has demonstrated that this domain is 
directly involved in proton translocation through F0 . The nt 
8993 T-»G (or C) mutation replaces the conserved leu156 by 
an arginine at a position close to that of the completely con-
served arg159, which is a key residue for proton translocation 
[20]. On the other hand, in the nt 9101 mutation a poorly 
conserved isoleucine at position 192 is replaced by a threo-
nine. 
Although both mutations lower the efficiency of oxidative 
phosphorylation, and both are located in the same region of 
subunit 6, their effects on ATP synthesis are fundamentally 
different. The fact that the rate of ATP synthesis was unable 
to keep up with an increase in respiratory rate in the NARP 
mutant strongly suggests inhibition of proton translocation by 
the F0 segment, as for the classical inhibitor oligomycin. As 
long as the rate of proton translocation by the respiratory 
chain does not exceed the impaired proton-translocating ca-
pacity of F0 due to this mutation, the ATP/2e~ ratio will 
remain normal. However, when this capacity is exceeded, 
the ATP/2e~ ratio declines, and some inhibition of state 3 
respiration also sets in due to respiratory control (cf. [13] 
and above). Our observation is in good agreement with the 
finding by Hartzog and Cain [21], who reported inhibition of 
proton translocation by membrane-reconstituted F1F0 from 
E. coli carrying the analogous mutation. It also agrees with 
previous reports on mitochondria carrying a similar level of 
heteroplasmy of this mutation, which showed lowered rates of 
ATP synthesis, ATP hydrolysis [22], and phosphorylating res-
piration [13], as well as a decreased ATP/2e~ ratio [12,13,22]. 
In complete contrast, the ilel92thr LHON mutation has the 
same type of effect as a low concentration of an uncoupling 
Table 1 
Efficiency of oxidative phosphorylation (ATP/2e~ ratio) in mitochondria from cybrid cells and lymphoblasts carrying the nt 9101 mutation 
Cell line Rate of electron transfer(nmol 2e /min'mg) ATP/2e-
Cybrid cell mitochondria (NADH-> cyt.c) 
nt 9101 [11] 
Control [11] 
Lymphoblast mitochondria (TMPD ->C>2) 
nt 9101 [7] 
Control [7] 
56 ± 6.8 
58 ± 8.8 
93 ±31 
110±23 
1.08±0.16 
1.59 ±0.26 
0.34 ±0.15 
0.69 ±0.19 
Values are means ±SD; number of separate experiments in parenthesis. 
Cybrid cell mitochondria were oxidising a-ketoglutarate by ferricyanide [5]; lymphoblast mitochondria respired with 0.2 mM TMPD (N,N,N',N'-
tetramethylene-p-phenylenediamine) plus ascorbate. 
A. Majander et al.lFEBS Letters 412 (1997) 351-354 353 
protonophore, where a limited proton leak conductance is 
created across the membrane. The lowered ATP/2e~ ratio is 
now due to the escape of protons across the membrane 
through this leak. Such an effect may be overcome by increas-
600 900 
900 
TMPD ( J I M ) 
Fig. 1. Relationship between rates of ATP synthesis and respiration 
in lymphoblastoid cell mitochondria, o, Rates of 02 consumption 
(nmol O/mgXmin); • . rates of ATP synthesis (nmol/mgXmin). Iso-
lated mitochondria were suspended in 0.25 M mannitol, 10 mM 
KC1, 0.2 mM EDTA, 1 mM MgCl2, 10 mM potassium phosphate, 
pH 7.2, with 0.5 mM ADP, 0.7 U/ml hexokinase (Boehringer-
Mannheim), 20 mM glucose, 10 uM rotenone, 0.3 Ug/ml antimycin, 
5 mM ascorbate and ATA^A^W-tetramethyl-p-phenylenediamine 
(TMPD). Values are means of 3-7 experiments ± SD. A: Control; 
B: nt 9101 mutant; C: nt 8993 mutant. Epstein-Barr virus trans-
formed lymphoblast cell lines [5] were from the LHON patient [9], 
from a NARP patient [12] and from 3 healthy control individuals. 
80% of mtDNA is mutated in the nt 8993 cell line [12]. 
< 
900 
TMPD (fxM) 
Fig. 2. The ATP/2e ratio as a function of respiratory rate. • . Con-
trols; o, nt 9101 mutant; A, nt 8993 mutant. Conditions as in 
Fig. 1. 
ing the respiratory velocity, which may increase the rate of 
generation of the electrochemical proton gradient over that of 
the leak conductance. The normal maximal rate of ATP syn-
thesis in this mutant agrees with the previously reported lack 
of marked changes in ATP hydrolysis activity [9]. A proton 
leak has been reported previously for a mutation in the E. coli 
a subunit [23], corresponding to Gly167Asp in the human sub-
unit. Interestingly, the amino acids in position corresponding 
to 168 and 194 have been shown to interact in the E. coli 
enzyme [24], so that the He192 LHON site may be close to 
that of Gly167 in the structure. These findings suggest that 
substituting a hydrophobic side chain with a hydrophilic 
one in this domain of subunit a introduces a proton leak 
through F0. Lewis et al. [25] proposed that the dielectric bar-
rier across F0 may be quite thin in the C-terminal domain of 
subunit a, relative to the thickness of the phospholipid bilayer. 
The NARP mutation is expected to be much more destruc-
tive than the LHON mutation from the viewpoint of energy 
metabolism. In LHON the functional defect can be overcome 
by an increased respiratory turnover, whereas in NARP the 
metabolic defect will be exacerbated whenever there is a high-
er demand on the rate of ATP synthesis. 
A lowered rate of oxidative ATP synthesis appears to be the 
common biochemical background of pathogenic importance 
in all LHON mutations studied thus far. This may result from 
inhibition of the respiratory chain, usually at complex I, but 
with an unaffected efficiency of oxidative phosphorylation [5]. 
Alternatively, as in the nt 9101 mutation described here, the 
same overall effect may be caused by a lowered efficiency of 
ATP synthesis, without inhibition of respiration. The net def-
icit is relatively small in all these LHON cases. Compensatory 
mechanisms were shown to minimise the metabolic conse-
quences of LHON mutations in complex I [5]. Interestingly, 
the specific features of the nt 9101 mutation also allow such 
compensation, although by an entirely different mechanism. 
The general view thus emerges that whilst the LHON mu-
tations are generally homoplasmic, the resulting primary de-
fect on the enzyme level can, in part, be metabolically com-
pensated. This may be a key feature contributing to the high 
tissue specificity of this disease, and to its low incidence 
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among individuals carrying the mutat ion. On the other hand, 
several other m t D N A mutat ions (e.g. the nt 8993 N A R P mu-
tation), lead to more severe metabolic defects which may be 
difficult to compensate for. In these cases the final clinical 
outcome, therefore, depends entirely on the degree of m t D N A 
heteroplasmy and its distribution in vital organs. 
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